Obstet Gynecol Sci 2023;66(5):449-454 https://doi.org/10.5468/ogs.23033 elSSN 2287-8580



Differential trend of mild and severe preeclampsia among nulliparous women: a population-based study of South Korea

Seyoung Kim, MPH¹, Ji Yeon Lee, MD, PhD², Taemi Kim, BA³, Eunseon Gwak, PhD⁴, Seung-Ah Choe, MD, PhD⁴

¹Department of Public Health Science, Graduate School of Public Health, Seoul National University, Seoul, ²Department of Obstetrics and Gynecology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, ³Department of Public Health, Korea University, ⁴Department of Preventive Medicine, Korea University College of Medicine, Seoul, Korea

We explored the annual risks of mild and severe preeclampsia (PE) among nulliparous women. Using the National Health Information Database of South Korea, 1,317,944 nulliparous women who gave live births were identified. Mild PE increased from 0.9% in 2010 to 1.4% in 2019 (*P* for trend=0.006), while severe PE decreased from 0.4% in 2010 to 0.3% in 2019 (*P*=0.049). The incidence of all types of PE (mild and severe) showed no linear change (*P*=0.514). Adjusted odds ratio (OR) of severe PE decreased in 2013 (0.68; 95% confidence interval [CI]: 0.60, 0.77) and beyond compared to that in 2010, while the OR of mild PE increased in 2017 (1.14; 95% CI: 1.06, 1.22) and beyond. Mild PE was found to be less likely to progress to the severe form since 2010; however, the overall risk of PE among women did not change.

Keywords: Preeclampsia; Nulliparity; Korea

Introduction

Preeclampsia (PE) is a multifactorial disorder that occurs during pregnancy and is characterized by hypertension and proteinuria after 20 weeks of gestation [1,2]. It brings about high morbidity and mortality in mothers and their babies, affecting 1-8% of pregnancies extending beyond 20 weeks [3]. Patients with severe PE require close monitoring for progression to an eclamptic event [4].

Historically, women with advanced age, obesity, nulliparity, underlying medical conditions, and assisted reproductive technology treatment are more likely to develop PE [5-8]. The overall incidence of hypertensive disorders during pregnancy has increased globally [9], while some high-income countries in northern Europe and Australia have reported a decreasing burden of the disease [10,11]. There are limited data regarding the recent epidemiology of mild and severe PE in highincome countries, where most pregnancies occur in women of advanced age. Here, we report trends in the incidence and risk of mild and severe PE among contemporary South Korean women.

Materials and methods

This is a retrospective observational study using the National Health Information (NHI) Database of NHI Service of South Korea, which covers approximately 97% of the Korean population. We identified a national cohort of 2,053,234 women who gave birth between January 2010 and December 2019 based on the childbirth treatment codes. Those without preconception health checkup data (n=300,570) were excluded. Women who had undergone a health examination at least once before their last menstrual period (which is estimated

Received: 2023. 01.26. Revised: 2023.03.01. Accepted: 2023.06.11. Corresponding author: Seung-Ah Choe, MD, PhD Department of Preventive Medicine, Korea University College of Medicine, 73 Goryeodae-ro, Seongbuk-gu, Seoul 02841, Korea E-mail: seungah@korea.ac.kr https://orcid.org/0000-0001-6270-5020

Copyright © 2023 Korean Society of Obstetrics and Gynecology

Articles published in Obstet Gynecol Sci are open-access, distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons. org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Monanisation 0531 054 054 055 <		No PE (n=1,296,725)	P for difference between no PE and mild PE	Mild PE (n=16,829)	<i>P</i> for difference between mild PE and severe PE	Severe PE (n=4,390)	P for difference between no PE and severe PE
26,02,2,0 $308,(1,8)$ $72(16)$ $323,84,52,5$ $3,44,20,8$ $736,81,7$ $323,84,52,0$ $3,44,20,8$ $736,81,7$ $673,34,52,0$ $8,147,48,4$ $736,18,1$ $123,34,52,0$ $3,11,22,2$ $11,11,25,3$ $156,60,1$ $1,536,(0,1)$ $907,54,7$ $21,11,25,3$ $1,536,(0,1)$ $907,54,7$ $21,637,94,9$ $20,899,74,94,9$ $1,587,(0,1)$ $907,54,9$ $20,91,94,94,78,94,94,94,78,94,94,94,78,94,94,94,78,94,94,78,94,94,78,94,94,74,94,94,94,74,94,94,74,94,94,74,94,94,94,94,94,94,94,94,94,94,94,94,94$	Woman's age (yr)		0.851		0.842		0.596
329.84 (5.5) 3,494 (2.6) 76 (18.1) 673934 (5.0) 8,147 (84.4) 2069 (47.6) 73934 (5.2) 3,11 (3.2.2) 2,099 (47.6) 2247 (51.3) 3,911 (3.2.2) 1,111 (2.5.3) 40.335 (3.1) 907 (5.4) 301 (6.9) 1,636 (0.1) 59,040 (5.1) 907 (5.4) 21 (0.5) 1,636 (0.1) 59,040 (5.1) 907 (5.4) 21 (0.5) 1,636 (0.1) 83,090 (6.17) 0.001 13,044 (7.5) 21 (0.5) 0 woke 83,904 (6.17) <001	20-24	26,062 (2.0)		308 (1.8)		72 (1.6)	
673343 (2.0) 8,47 (48,4) 2008 (476) 224 /15 (17.3) 391 (2.32) 1,111 (2.53) 224 /15 (17.3) 907 (5.4) 301 (6.9) 224 /15 (17.3) 907 (5.4) 301 (6.9) 1,035 (0.1) 59 (0.4) 21 (0.5) 1,035 (0.1) 59 (0.4) 21 (0.5) 1,035 (0.1) 59 (0.4) 21 (0.5) 1,035 (0.1) 2004 (6.17) 2001 21 (0.5) 0 owker 339,034 (6.17) <0.01	25-29	329,848 (25.5)		3,494 (20.8)		796 (18.1)	
224,15 (1.2) 3,911 (2.2) 1,111 (2.3) 40,335 (3.1) 907 (5,4) 30 (6.9) 1,656 (0.1) 59 (4) 30 (6.9) 1,656 (0.1) 59 (4) 21 (0.5) 1,656 (0.1) 59 (4) 21 (0.5) 1,656 (0.1) 6001 1,964 (7.8) 21 (0.5) advore 8330 (4,47) 6001 1,964 (7.8) 21 (0.5) aehthcare coverage 833 (94 (4.7) 6001 1,267 (9.6) 21 (7.5) sectivers 1,297 (1.8) 0.0137 16,800 (99.8) 0.013 21 (7.5) sectivers 1,597 (1.6) 0.01 29 (0.2) 18 (0.4) 18 (0.4) sectivers 1,587 (0.1) 0.01 3,281 (1.5) 18 (0.4) 18 (0.4) norme ^b 1,587 (0.1) 2,796 (1.7) 2,796 (1.6) 18 (0.4) 18 (0.4) norme ^b 2333173 (272) 2,791 (9.2) 2,796 (1.6) 18 (0.4) 18 (0.4) norme ^b 233173 (272) 2,918 (1.6) 2,918 (1.6) 12 (1.6) 18 (0.2)	30-34	673,934 (52.0)		8,147 (48.4)		2,089 (47.6)	
40.335 (3.1) 907 (5.4) 301 (6.9) 1,536 (0.1) 59 (0.4) 59 (0.4) 21 (0.5) 1,536 (0.1) 59 (0.4) 21 (0.5) 21 (0.5) Atoverter 959 890 (74.0) 6001 13,094 (77.8) 21 (0.5) Atoverter 839 094 (6.7) 6001 10,236 (6.08) 0.286 2,156 (1.6) Atoverter 839 094 (6.7) 6001 10,236 (6.08) 0.286 2,715 (61.8) Atoverter 839 094 (6.7) 6001 10,236 (6.08) 0.286 2,715 (61.8) Societes 1,587 (0.1) 20 0.317 20 20 2,715 (61.8) Societes 1,587 (0.1) 29 0.20 9.8 2,715 (61.8) 2,155 (61.8) Atoverter 1,587 (0.1) 20 2,212 (7.2) 12,87 (7.1) 13.00 (7.6) 2,165 (1.6) 2,155 (53.6) Atoverter 23,173 (7.2) 23,21 (19.2) 23,21 (19.2) 12,256 (35.4) 12,256 (35.4) Atoverter 23,21 (7.1) 22,23 (7.5) 23,21 (7.6) 22,24 (7.1) <	35-39	224,715 (17.3)		3,911 (23.2)		1,111 (25.3)	
1,53 (0.1) 59 (0.4) 21 (0.5) discle of Seoul metropolitan area 993 90 (7.4) 0001 3457 (73.4) 21 (0.5) divoker 993 90 (7.4) <0001	40-44	40,335 (3.1)		907 (5.4)		301 (6.9)	
discle of Seoul metropolitan area 959.80 (4.0) 6001 13.094 (77.8) 6001 3487 (79.4) di worker 833.094 (64.7) <0001	45-49	1,636 (0.1)		59 (0.4)		21 (0.5)	
d worket B33,094 (6.1') 0.236 (60.8) 0.266 2.715 (61.8) reithreacemene 1,295,138 (99.9) 0.317 16,800 (99.8) <0.001	Living outside of Seoul metropolitan area		<0.001	13,094 (77.8)	<0.001	3,487 (79.4)	<0.001
mentificance coverage scribles [1,295,138,99;9] 0.317 (5,800,99;8) (312,99;6) Jaid beneficiary 1,587 (0.1) 29 (0.2) (4,372,99;6) (18 (0.4)) Jaid beneficiary 1,587 (0.1) 2,901 32,81 (195) (18 (0.4)) wesh 223,173 (27.2) 4,842 (28.8) (1,225 (27.9)) (125 (27.9)) wesh 235,173 (27.2) 4,942 (38.9) (1,225 (37.4)) (125 (37.4)) wesh 235,173 (27.2) 4,942 (38.9) (1,225 (37.4)) (1,225 (37.4)) wesh 222,462 (17.1) <001	Employed worker	839,094 (64.7)	<0.001	10,236 (60.8)	0.286	2,715 (61.8)	<0.001
scribes 1,295,138 (99.9) 0.317 16,800 (99.8) (0.001 (3.322 (99.6) 18 (0.4) (3.322 (99.6) (3.24) (3.24) (3.24) (3.24) (3.24) (3.24) (3.23) (3.21) (3.22) (3.24) (3.23) (3.21) (3.22) (3.24) (3.23) (3.21) (3.22) (3.24) (3.23) (3.22) (3.24) (3.23) (3.21) (3.22) (3.24) (3.21) (3.22) (3.24) (3.21) (3.22) (3.24) (3.21) (3.22) (3.24) (3.21) (3.22) (3.21) (3.22) (3.21) (3.22) (3.21) (3.22) (3.21) (3.22) (3.21) (3.22) (3.21) (3.2	Type of healthcare coverage						
I alid beneficiary $1,587 (0.1)$ $29 (0.2)$ $18 (0.4)$ income ^b $2,28,16 (17.6)$ $2,001$ $3,281 (19.5)$ $916 (20.9)$ very $2,28,16 (17.6)$ $4,842 (28.8)$ $1,225 (27.9)$ very $3,33,173 (27.2)$ $4,842 (28.8)$ $1,225 (37.9)$ very $2,22,462 (17.1)$ $2,924 (38.0)$ $1,255 (35.4)$ hery $2,22,462 (17.1)$ $2,799 (16.3)$ $1,255 (35.4)$ hery $2,22,462 (17.1)$ $2,799 (16.3)$ $1,255 (35.4)$ hery $2,22,462 (17.1)$ $2,799 (16.3)$ 0.01 hery $2,22,462 (17.1)$ $2,799 (16.3)$ 0.01 hery $1,587 (0.1)$ $2,90 (0.2)$ $0.350 (10.2)$ hery $1,587 (0.1)$ $2,90 (0.2)$ $0.350 (0.2)$ hery $1,264,330 (97.5)$ $1,318 (7.8)$ -6.001 hery $1,264,330 (97.5)$ $1,318 (7.8)$ -6.001 hery $3,2395 (2.5)$ $1,318 (7.8)$ -6.001 hery $3,2395 (2.5)$ $1,318 (7.8)$ -6.001 hery $2,2780 (9.7)$ $2,2780 (10.7)$ -6.001 hery $2,2780 (10.7)$ -6.001 -6.001 hery $2,2780 (10.7)$ -6.001 -6.001 hery $-1,318 (7.8)$ $-1,318 (7.8)$ hery $-1,318 (7.8)$ -6.001 hery $-1,318 (7.8)$	NHI subscribers	1,295,138 (99.9)	0.317	16,800 (99.8)	<0.001	4,372 (99.6)	<0.001
income ^b $228, 166 (17.6)$ < 0.010 $3, 281 (19.5)$ 0.182 $916 (20.9)$ west) $235, 173 (27.2)$ $4, 842 (28.8)$ $1, 225 (27.9)$ $1, 255 (35.4)$ hest) $492, 244 (8.0)$ $4, 842 (38.9)$ $1, 255 (35.4)$ $1, 255 (35.4)$ hest) $222, 462 (17.1)$ $2, 749 (16.3)$ $1, 255 (35.4)$ hest) $222, 462 (17.1)$ $2, 749 (16.3)$ $693 (15.8)$ hest) $222, 462 (17.1)$ 2001 $29 (02)$ $693 (15.8)$ hest) $222, 462 (17.1)$ < 0.001 $29 (02)$ $693 (15.8)$ hest) $1, 587 (0.1)$ < 0.001 $29 (02)$ $693 (15.8)$ hest) $1, 587 (0.1)$ < 0.001 $29 (02)$ $693 (15.8)$ hest) $1, 264, 330 (97.5)$ $1, 511 (92.2)$ 6001 $3, 233 (15.8)$ hest) $1, 264, 330 (97.5)$ $1, 318 (7.8)$ $401 (10.5)$ henty status $32, 335 (2.5)$ $1, 318 (7.8)$ $401 (10.5)$ henty status $1, 264, 300 (97.5)$ $1, 318 (7.8)$ $401 (10.5)$ henty status $1, 264, 300 (97.5)$ $1, 318 (7.8)$ $401 (10.5)$ henty status $1, 264, 300 (97.5)$ $1, 291 (97.4)$ $1, 700 (88.9)$ henty status $1, 264, 900 (10, 90$	Medical aid beneficiary	1,587 (0.1)		29 (0.2)		18 (0.4)	
west) 228,166 (17.6) <0.001 3.281 (19.5) 0.182 916 (20.9) 353,173 (27.2) 353,173 (27.2) 4,842 (28.8) 1,225 (27.9) hest) 492,924 (38.0) 5,957 (35.4) 1,255 (35.4) hest) 222,462 (17.1) 2,749 (16.3) 1,255 (35.4) hest) 222,462 (17.1) 2,749 (16.3) 693 (15.8) hest) 222,462 (17.1) 2,001 2,020 693 (15.8) hest) 21,587 (0.1) 2,001 2,020 693 (15.8) hest) 2,001 2,010 2,020 1,010,1 on 1,1587 (0.1) 1,318 (7.8) 461 (10.5) on oy status 32,335 (2.5) 1,318 (7.8) 461 (10.5) nony status 32,335 (2.5) 1,318 (7.8) 461 (10.5) si index (kg/m) 32,335 (2.5) -1,318 (7.8) 461 (10.5) nony status 32,335 (2.5) -1,318 (7.8) 461 (10.5) si index (kg/m) -1,218 (2.5) -1,318 (7.8) 461 (10.5) si index (kg/m) -1,328 (1.1)	Level of income ^{b)}						
	1Q (lowest)	228,166 (17.6)	<0.001	3,281 (19.5)	0.182	916 (20.9)	<0.001
492,924 (38.0)5,957 (35.4)1,556 (35.4)het) $222,462 (17.1)$ $2,749 (16.3)$ $693 (15.8)$ het) $222,462 (17.1)$ $2,749 (16.3)$ $693 (15.8)$ het) $1,587 (0.1)$ $2,749 (16.3)$ $693 (15.8)$ het) -0.01 $29 (0.2)$ 0.250 $18 (0.4)$ het) -0.01 -0.01 -0.01 -0.01 het) -0.01 -0.01 -0.01 -0.01 het) -0.01 $-1,264,330 (97.5)$ $1,318 (7.8)$ -0.01 het) $-3,235 (2.5)$ $-1,318 (7.8)$ -0.01 -0.01 het) $-2,235 (2.5)$ $-1,218 (7.8)$ -0.01 -0.01 het) $-2,335 (2.5)$ -0.01 -0.01 -0.01 het) $-2,335 (2.5)$ -0.01 -0.01 -0.01 het) $-2,335 (2.5)$ -0.01 -0.01 -0.01 het) $-2,325 (1.3)$ -0.01 -0.01 -0.01 het) -0.01 -0.01 -0.01	2Q	353,173 (27.2)		4,842 (28.8)		1,225 (27.9)	
het) $222,462 (17.1)$ $2,749 (16.3)$ $693 (15.8)$ i $1,587 (0.1)$ $c0.01$ $29 (0.2)$ $18 (0.4)$ i <td< td=""><td>3Q</td><td>492,924 (38.0)</td><td></td><td>5,957 (35.4)</td><td></td><td>1,556 (35.4)</td><td></td></td<>	3Q	492,924 (38.0)		5,957 (35.4)		1,556 (35.4)	
	4Q (richest)	222,462 (17.1)		2,749 (16.3)		693 (15.8)	
on (-0.001) (-0.001) on $(-1,264,330(97.5))$ $(-1,5511(92.2))$ $(-1,291(95.5))$ e gestation $(-1,264,330(97.5))$ $(-1,318(7.8))$ $(-461(10.5))$ e gestation $(-2,325(2.5))$ $(-1,318(7.8))$ $(-61(10.5))$ nony status $(-1,318(7.8))$ $(-1,318(7.8))$ $(-61(10.5))$ sindex (kg/m ²) (-0.001) (-0.001) (-0.001) sindex (kg/m ²) (-0.001) $(-0.00$	Disability	1,587 (0.1)	<0.001	29 (0.2)	0.250	18 (0.4)	<0.001
	Plurality		<0.001		<0.001		<0.001
$ \begin{array}{ccccccc} 32,395(2.5) & 1,318(7.8) & 461(10.5) \\ \\ m^2 & & & & & & & & & & & & & & & & & & &$	Singleton	1,264,330 (97.5)		15,511 (92.2)		3,929 (89.5)	
m ²) <- 0.001 <- 0.001 <- 0.001 > > > >							

Vol. 66, No. 5, 2023

Sevoung Kim, et al. Incidence of mild and severe preeclampsia

	No PE (n=1,296,725)	<i>P</i> for difference between no PE and mild PE	Mild PE (n=16,829)	<i>P</i> for difference between mild PE and severe PE	Severe PE (n=4,390)	<i>P</i> for difference between no PE and severe PE
>30	16,543 (1.3)		880 (5.2)		163 (3.7)	
Fasting blood glucose (mg/dL)		<0.001		0.454		<0.001
<100	1,216,377 (93.8)		15,154 (90.1)		3,945 (89.8)	
100-126	75,297 (5.8)		1,438 (8.5)		372 (8.5)	
≥126	5,051 (0.4)		237 (1.4)		73 (1.7)	
Past smoking	75,630 (5.8)	<0.001	1,139 (6.8)	<0.001	213 (4.9)	0.011

based on the date of childbirth [12]), and therefore had available baseline clinical data, were then selected among the pregnancy cases. We excluded women with a history of prior childbirth because we could not retrieve information on prior PE, an established risk factor for PE, for multiparous women who gave birth before 2010. Inclusion criteria were women who were between 20 and 49 years of age and nulliparous. This yielded a final study population of 1,317,944 women.

We included maternal age at birth, relative income level (in deciles), employment status, living in the Seoul metropolitan area, plurality, prepregnancy body mass index, prior history of smoking, fasting blood glucose level, and year of childbirth in the explanatory model. We identified patients who were diagnosed with PE during pregnancy based on the International Classification of Disease (ICD), 10th revision, codes (ICD-10: 014.0, 014.1, 014.2, and 014.9). We defined severe PE patients as those with a diagnostic code for PE as well as a prescription code for intravenous magnesium sulfate (MgSO₄) [13,14], because its use to prevent eclamptic seizure is the essential feature of the "severity" of the condition. Mild PE was defined by the presence of only one diagnostic code.

Descriptive statistics were calculated based on the presence of mild or severe PE. Annual odds ratios (ORs) and 95% confidence intervals (CIs) for total, mild, and severe PE were computed adjusting for all the individual covariates. Effect modification by maternal age was assessed in the association between age and PE. We used the SAS statistical program (version 9.4; SAS Institute, Cary, NC, USA).

Results

lowest guartile; 20, second guartile; 30, third guartile; 40, fourth guartile.

^{b)}10,1

Frequencies may not sum to full sample size due to missing data.

Among the 1,317,944 nulliparous women who gave live births, the majority were aged <35 years (67.3%), had singleton pregnancies (97.4%), and lived outside of the Seoul capital area (74.1%). Income was lower than the national median in almost half of the population (44.9%). The risk of PE (3.4%) and severe PE (1.2%) was highest when maternal age was 45-49 years, which was almost three times higher compared to that in women 20-24 years old.

When the study population was classified by PE diagnosis, the proportion of women aged \geq 35 years was higher in the mild (29.0%) and severe PE (32.7%) groups than in the no PE group (20.5%; Table 1). The distribution of maternal age

Vol. 66, No. 5, 2023




Fig. 1. Adjusted odds ratios of mild and severe preeclampsia for year of childbirth among nulliparous women, the National Health Information (NHI) Database of NHI Service of South Korea (n=1,317,944).

was not different between the no PE, mild PE, and severe PE groups. Generally, women who were diagnosed with severe PE tended to be medical aid beneficiaries, showed the lowest income quartile, and had a higher likelihood for disability, multiple gestations, and impaired glucose intolerance, compared to those with a diagnosis of mild or no PE.

The overall cumulative incidences of mild PE and severe PE were 1.3% and 0.3%, respectively. Mild PE increased from 0.9% in 2010 to 1.4% in 2019 (P for trend=0.006), while severe PE decreased from 0.4% in 2010 to 0.3% in 2019 (P=0.049). The incidence of all types of PE (mild and severe) showed no linear change (P=0.514). Compared to that in 2010, the adjusted OR of severe PE was lower in 2013 (OR: 0.68; 95% CI: 0.60, 0.77) and beyond, while the OR of mild PE was higher in 2017 (1.14; 95% CI: 1.06, 1.22; Fig. 1) and beyond. The OR for all PE in the period 2011-2017 remained lower than that in 2010, and returned to the 2010 levels during 2018-2019. We assessed the effect of advanced age at birth on the association between the year of birth and PE. The trend of adjusted OR for all PE per year did not significantly differ between women aged <35 years and those aged ≥35 years.

Discussion

We observed different patterns in the incidence and risk of

mild and severe PE in South Korean women over the past decade. Despite the overall increase in the number of older mothers, the crude incidence of all types of preeclampsia did not increase. When we adjusted for individual risk factors, the risk of mild PE increased, whereas that of severe PE decreased, suggesting that patients with mild PE have been less likely to progress to severe PE since 2010.

The decrease in severe PE can be attributed to reduced progression of mild PE to the severe form or to the physicians' decision to induce childbirth in advance. As the annual incidence of induction of labor in nulliparous women decreased during the study period (from 22.8% in 2010 to 20.3% in 2019) [15], the decrease in severe PE would be less likely due to labor induction. The decreasing risk of severe PE may be explained by the widespread use of aspirin in high-risk pregnancies and the higher coverage of antenatal voucher programs provided by the South Korean government [16]. Because data on aspirin use during pregnancy were unavailable, we could not assess its impact. In South Korea, a universal voucher scheme was initiated in 2008 to alleviate the financial burden of pregnant women for antenatal care and birth services [17]. We previously reported a significant reduction in preeclampsia in the general population after the introduction of the voucher scheme, which remained significant after controlling for individual risk factors [14].

The results of the present study should therefore be interpreted with caution. There may have been a tendency

Seyoung Kim, et al. Incidence of mild and severe preeclampsia

toward overreporting by physicians, and misclassification or miscoding may have affected the results of this study. Given that the incidence of mild PE was reported to be 2.5-4 times higher than that of severe PE in prior studies [18-20], we believe that the possibility of misclassification would have been minimal. Second, our operative definition of severe PE based on the prescription of MgSO₄ may have been affected by the recommendation of the United States. Food and Drug Administration against prolonged use of MgSO₄ to stop preterm labor due to bone changes in exposed babies in 2013. However, given the consistent incidence of severe PE since 2012, we believe that the decreasing trend in the adjusted risk of severe PE is less likely to be attributable to this recommendation.

In conclusion, mild PE has been less likely to progress to the severe form since 2010. However, the overall risk of PE has not changed among contemporary South Korean women. Further studies identifying the factors that reduce the risk of progression to severe PE are needed to understand the epidemiological changes in this condition.

Conflict of interest

All authors declare that they have no conflict of interest.

Ethical approval

The study protocol was reviewed and approved by the Institutional Review Board of Korea University (IRB-2020-0285).

Patient consent

Not applicable.

Funding information

This research was supported by the National Research Foundation of Korea grant (2018R1D1A1B07048821 & 2022R1A2C1006364).

References

- 1. Atallah A, Lecarpentier E, Goffinet F, Doret-Dion M, Gaucherand P, Tsatsaris V. Aspirin for prevention of preeclampsia. Drugs 2017;77:1819-31.
- 2. Ramos JGL, Sass N, Costa SHM. Preeclampsia. Rev Bras Ginecol Obstet 2017;39:496-512.
- 3. Freeman RK, Nageotte MP. Comments on American College of Obstetricians and Gynecologists practice bulletin no. 106. Am J Obstet Gynecol 2010;202:411-2.
- 4. Jung E, Romero R, Yeo L, Gomez-Lopez N, Chaemsaithong P, Jaovisidha A, et al. The etiology of preeclampsia. Am J Obstet Gynecol 2022;226:S844-66.
- 5. Sole KB, Staff AC, Laine K. Maternal diseases and risk of hypertensive disorders of pregnancy across gestational age groups. Pregnancy Hypertens 2021;25:25-33.
- Brown MA, Magee LA, Kenny LC, Karumanchi SA, Mc-Carthy FP, Saito S, et al. Hypertensive disorders of pregnancy: ISSHP classification, diagnosis, and management recommendations for international practice. Hypertension 2018;72:24-43.
- Bartsch E, Medcalf KE, Park AL, Ray JG. Clinical risk factors for pre-eclampsia determined in early pregnancy: systematic review and meta-analysis of large cohort studies. BMJ 2016;353:i1753.
- Petersen SH, Bergh C, Gissler M, Åsvold BO, Romundstad LB, Tiitinen A, et al. Time trends in placenta-mediated pregnancy complications after assisted reproductive technology in the Nordic countries. Am J Obstet Gynecol 2020;223:226.e1-226.e19.
- 9. Wang W, Xie X, Yuan T, Wang Y, Zhao F, Zhou Z, et al. Epidemiological trends of maternal hypertensive disorders of pregnancy at the global, regional, and national levels: a population-based study. BMC Pregnancy Childbirth 2021;21:364.
- Roberts CL, Ford JB, Algert CS, Antonsen S, Chalmers J, Cnattingius S, et al. Population-based trends in pregnancy hypertension and pre-eclampsia: an international comparative study. BMJ Open 2011;1:e000101.
- 11. Sole KB, Staff AC, Räisänen S, Laine K. Substantial decrease in preeclampsia prevalence and risk over two decades: a population-based study of 1,153,227 deliveries in Norway. Pregnancy Hypertens 2022;28:21-7.
- 12. Noh Y, Choe SA, Kim WJ, Shin JY. Discontinuation and re-initiation of antidepressants during pregnancy: a na-

Vol. 66, No. 5, 2023

tionwide cohort study. J Affect Disord 2022;298:500-7.

- Choe SA, Min HS, Cho SI. The income-based disparities in preeclampsia and postpartum hemorrhage: a study of the Korean National Health Insurance cohort data from 2002 to 2013. Springerplus 2016;5:895.
- 14. Choe SA, Min HS, Cho SI. Decreased risk of preeclampsia after the introduction of universal voucher scheme for antenatal care and birth services in the Republic of Korea. Matern Child Health J 2017;21:222-7.
- 15. Health Insurance Review & Assessment Service. Healthcare service provision statistics (tests and surgeries) [Internet]. Wonju: Health Insurance Review & Assessment Service; c2023 [cited 2023 Mar 3]. Available from: https://opendata.hira.or.kr/op/opc/olapDiagBhvInfoTab1. do#none.
- Lee SY, Choi IS. Policy support for medical expenses on pregnancy and delivery: the kookmin haengbok card program [Internet]. Sejong: Korea Institute for Health and Social Affairs; c2016 [cited 2023 Mar 3].

Available from: https://repository.kihasa.re.kr/handle/201002/20819.

- 17. National Legal Information Center. Mother and child health act [Internet]. Sejong: National Legal Information Center; c2021 [cited 2023 Mar 3]. Available from: https://www.law.go.kr/LSW/eng/engLsSc.do?menuId=2 §ion=lawNm&query=MOTHER+AND+CHILD+HEALT H+ACT&x=0&y=0#liBgcolor1.
- Xiao J, Shen F, Xue Q, Chen G, Zeng K, Stone P, et al. Is ethnicity a risk factor for developing preeclampsia? An analysis of the prevalence of preeclampsia in China. J Hum Hypertens 2014;28:694-8.
- 19. Vata PK, Chauhan NM, Nallathambi A, Hussein F. Assessment of prevalence of preeclampsia from Dilla region of Ethiopia. BMC Res Notes 2015;8:816.
- 20. David M, Naicker T. The complement system in preeclampsia: a review of its activation and endothelial injury in the triad of COVID 19 infection and HIV-associated preeclampsia. Obstet Gynecol Sci 2023;66:253-69.